SANFORD D MARKOWITZ, MD
Osteopathic Medicine at Euclid Ave, Cleveland, OH
License number
Ohio 35-055623
Category
Osteopathic Medicine
Type
Hematology & Oncology
Address
Address
11100 Euclid Ave, Cleveland, OH 44106
Phone
(216) 844-8500
Personal information
See more information about SANFORD D MARKOWITZ at radaris.comName
Address
Phone
28950 Bolingbrook Rd #533, Cleveland, OH 44124
28950 Bolingbrook Rd, Cleveland, OH 44124
Organization information
See more information about SANFORD D MARKOWITZ at bizstanding.comSanford D Markowitz
11100 Euclid Ave, Cleveland, OH 44106
Industry:
Internist
Phone:
(216) 844-3951 (Phone)
University Hospitals - Sanford D Markowitz MD
11100 Euclid Ave, Cleveland, OH 44106
Categories:
Internal Medicine Physicians & Surgeons, Oncology Physicians & Surgeons
Phone:
(216) 844-7868 (Phone)
Professional information
Dr. Sanford D Markowitz, Cleveland OH - MD (Doctor of Medicine)
Specialties:
Oncology, Medical Oncology
Address:
11100 Euclid Ave, Cleveland 44106
(216) 844-8236 (Phone), (216) 844-8230 (Fax)
(216) 844-8236 (Phone), (216) 844-8230 (Fax)
Certifications:
Internal Medicine, 1984, Medical Oncology, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
11100 Euclid Ave, Cleveland 44106
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland 44106
University Hospitals Case Medical Center
11100 Euclid Ave, Cleveland 44106
Education:
Medical School
Yale University School Of Medicine
Graduated: 1980
University Of Chicago
Graduated: 1982
Graduated: 1984
National Cancer Institute
Yale University School Of Medicine
Graduated: 1980
University Of Chicago
Graduated: 1982
Graduated: 1984
National Cancer Institute
Methods Of Diagnosis Of Colorectal Cancer, Compositions And Methods Of Screening For Modulators Of Colorectal Cancer
US Patent:
2004006, Apr 1, 2004
Filed:
Dec 12, 2002
Appl. No.:
10/318578
Inventors:
David Mack - Menlo Park CA, US
Sanford Markowitz - Pepper Pike OH, US
Thomas Ried - Bethesda MD, US
Sanford Markowitz - Pepper Pike OH, US
Thomas Ried - Bethesda MD, US
International Classification:
C12Q001/68
US Classification:
435/006000
Abstract:
Described herein are methods and compositions that can be used for diagnosis and treatment of colorectal cancer. Also described herein are methods that can be used to identify modulators of colorectal cancer.
Sanford Markowitz, Cleveland OH
Specialties:
Internal Medicine, Medical Oncology, Hematology & Oncology, Hematology
Work:
Case Western Reserve University
11100 Euclid Ave, Cleveland, OH 44106 Wolstein Research Building
2103 Cornell Rd, Cleveland, OH 44106
11100 Euclid Ave, Cleveland, OH 44106 Wolstein Research Building
2103 Cornell Rd, Cleveland, OH 44106
Education:
Yale University (1980)
Cancer Diagnosis And Therapy Based On Mutations In Tgf- Receptors
US Patent:
6630326, Oct 7, 2003
Filed:
Jun 13, 2001
Appl. No.:
09/878905
Inventors:
Sanford D. Markowitz - Pepper Pike OH
Michael G. Brattain - San Antonio TX
James K. V. Willson - Shaker Heights OH
Michael G. Brattain - San Antonio TX
James K. V. Willson - Shaker Heights OH
Assignee:
Case Western Reserve University - Cleveland OH
Medical College of Ohio - Toledo OH
Medical College of Ohio - Toledo OH
International Classification:
C12N 1563
US Classification:
435 691, 435325, 530350
Abstract:
This invention is based on the discovery that the type II TGF receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
Methods And Compositions For Detecting Cancers
US Patent:
2004005, Mar 18, 2004
Filed:
Jun 5, 2003
Appl. No.:
10/456930
Inventors:
Sanford Markowitz - Pepper Pike OH, US
Assignee:
Case Western Reserve University - Cleveland OH
International Classification:
C12Q001/68, C07H021/04, C12P021/02, C12N005/06, C07K016/30, C07K014/705
US Classification:
435/006000, 435/069100, 435/320100, 435/325000, 530/350000, 530/388100, 536/023500
Abstract:
In certain aspects, the invention provides isolated SLC5A8 (also referred to as Hui1) nucleic acid molecules, which encode novel sodium solute symporter members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing SLC5A8 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a SLC5A8 gene has been introduced or disrupted. The invention still further provides isolated SLC5A8 proteins, fusion proteins, antigenic peptides, and anti-SLC5A8 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. In other aspects, the invention provides methods and compositions for detecting and treating SLC5A8-associated cancer. Differential methylation of the SLC5A8 nucleotide sequences has been observed in SLC5A8-associated cancer, such as colon cancer, breast cancer, thyroid cancer, or stomach cancer.
Methods And Compositions For Detecting Colon Cancers
US Patent:
8221977, Jul 17, 2012
Filed:
May 11, 2011
Appl. No.:
13/105588
Inventors:
Sanford D. Markowitz - Pepper Pike OH, US
Assignee:
Case Western Reserve University - Cleveland OH
International Classification:
C12Q 1/68
US Classification:
435 61
Abstract:
This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.
Methods And Compositions For Detecting Colon Cancers
US Patent:
2009006, Mar 5, 2009
Filed:
Jul 31, 2008
Appl. No.:
12/221297
Inventors:
Sanford D. Markowitz - Pepper Pike OH, US
Wei-Dong Chen - South Euclid OH, US
Wei-Dong Chen - South Euclid OH, US
International Classification:
C12Q 1/68, C12N 15/11, C07H 21/04, G01N 33/00, C07H 1/00
US Classification:
435 6, 536 235, 536 2433, 436 94, 536 253
Abstract:
This application describes methods and compositions for detecting and treating HLTF-associated neoplasia. Differential methylation of the HLTF nucleotide sequences has been observed in HLTF-associated neoplasia such as colon neoplasia.
Cancer Diagnosis And Therapy Based On Mutations In Tgf-Beta Receptors
US Patent:
2004003, Feb 26, 2004
Filed:
Aug 21, 2003
Appl. No.:
10/646640
Inventors:
Sanford Markowitz - Pepper Pike OH, US
Michael Brattain - San Antonio TX, US
James Willson - Skaker Heights OH, US
Michael Brattain - San Antonio TX, US
James Willson - Skaker Heights OH, US
International Classification:
C12Q001/68, G01N033/574
US Classification:
435/006000, 435/007230
Abstract:
This invention is based on the discovery that the type II TGF receptor (RII) is a cancer suppressor gene which is genetically inactivated (mutated) in approximately 25% of colon cancers, including nearly all colon cancers of the class identified as mutator/microsatellite instability/RER. Methods are provided for detecting inactivation of RII for use in cancer diagnosis or prognosis.
Methods And Compositions For Detecting Colon Cancers
US Patent:
7964353, Jun 21, 2011
Filed:
Jan 30, 2009
Appl. No.:
12/322202
Inventors:
Sanford D. Markowitz - Pepper Pike OH, US
Assignee:
Case Western Reserve University - Cleveland OH
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia.
Methods For Diagnosing And Treating Cancers
US Patent:
2011002, Feb 3, 2011
Filed:
Sep 5, 2008
Appl. No.:
12/676817
Inventors:
Sanford D. Markowitz - Pepper Pike OH, US
Joseph Willis - Shaker Heights OH, US
Dawn Dawson - Cleveland Heights OH, US
Joseph Willis - Shaker Heights OH, US
Dawn Dawson - Cleveland Heights OH, US
International Classification:
A61K 39/395, G01N 33/68, G01N 33/566, G01N 33/574, A61K 38/02, A61K 31/7105, A61K 31/713, A61K 31/711, A61P 35/00
US Classification:
4241391, 436 86, 436501, 435 79, 514 193, 514 44 R, 514 44 A
Abstract:
This disclosure provides methods and compositions for inhibiting immune responses. The disclosure also provides methods and compositions for inhibiting graft rejection and promoting or prolonging graft survival.